SHRM

Champignon Brands

Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence

VANCOUVER, British Columbia, Aug. 27, 2020 -- Champignon Brands Inc. (CSE: SHRM) (the “Company” or “Champignon”) is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic starting in September 2020. Ketamine was declare... Read More...

Champignon Announces Regulatory Review

VANCOUVER, British Columbia, June 22, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF) announces that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”).  The review relates to the Company’s disclosure obligations since it became ... Read More...

Champignon Announces Closing of $15 Million Bought Deal Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, June 11, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is please... Read More...

Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio

VANCOUVER, British Columbia, June 08, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is pleased to announce it has selected Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemi... Read More...

Champignon Announces Voluntary Share Lock-Up; Retains Gold Standard Media, LLC for Financial Marketing Services

VANCOUVER, British Columbia, May 29, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announces that certain shareholders have agreed to a voluntary resale restriction period covering 17,8... Read More...

Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors

VANCOUVER, British Columbia, May 25, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to augment its board of directors through the appointment of accomplished business executives and ... Read More...

Champignon Sponsors Non-profit Coalition, TheraPsil – Medical Psilocybin Access Project for Palliative Cancer Patients and Health Professionals

VANCOUVER, British Columbia, May 18, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to sponsor TheraPsil, a BC-based non-profit coalition of healthcare professionals, policy-makers ... Read More...

Champignon Expands to U.S., To Acquire California Based Ketamine Centre – Wellness Clinic of Orange County

VANCOUVER, British Columbia, May 12, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine is pleased to announce that it has executed a term sheet (the “Term Sheet”) with California, U.S. based Welln... Read More...

Le traitement à base de kétamine de Champignon sera distribué par une importante chaîne de pharmacie canadienne et la compagnie annonce la clôture de la transaction d’AltMed

VANCOUVER, Colombie-Britannique, April 30, 2020 -- Champignon Brands Inc. (« Champignon » ou la « société ») (CSE : SHRM) (FWB : 496) (OTCQB : SHRMF), une société des sciences de l’optimisation humaine concentrée sur l’application de nouveaux protocoles de traitement naturels mettant l’accent sur la médecine psychédélique afin de traiter ... Read More...

Champignon Secures Stable Psilocybin Supply Under DEA Schedule I License for TBI/PTSD Studies at the University of Miami

VANCOUVER, British Columbia, April 22, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to advan... Read More...

Champignon Appoints Former President of Red Bull Canada to Special Advisory Committee

VANCOUVER, British Columbia, April 16, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, has further bolste... Read More...

Champignon to Acquire AltMed Capital Corp.

VANCOUVER, British Columbia, April 09, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to accel... Read More...